Introduction
Biology of incretin hormones
Incretin-related drugs
Administration | Clearance | Side effects | ||
---|---|---|---|---|
GLP-1R agonist | Subctaneous | Weight loss | Gastrointestinal tract (GIT) | |
Exenatide | Twice a day, once a week | Renal | + | ++/±* |
Liraglutide | Once a day | Extrarenal | + | + |
DPP-4 inhibitor | Oral | → | → | |
Sitagliptin | Once a day | Renal | → | → |
Vildagliptin | Twice a day | Renal | → | → |
Saxagliptin | Once a day | Renal | → | → |
Linagliptin | Once a day | Extrarenal | → | → |
Anagliptin | Twice a day | Renal | → | → |
Teneligliptin | Once a day | Extrarenal > renal | → | → |
Alogliptin | Once a day | Renal | → | → |
Possible effects of incretins on vessels
Incretin and endothelial cells (in vitro)
The in vivo or ex vivo endothelial function
Other possible effects of Incretins on the endothelium, possible effects of incretins on vessels and clinical data
Lowering blood pressure
Lipid metabolism
Clinical data
Author | Subjects | n | Endothelial function | Medication | Control | Duration | Result |
---|---|---|---|---|---|---|---|
Basu A et al.[41] |
T2DM
|
29
|
Strain-gauged plethysmography
|
GLP-1
|
Placebo
|
240 min
|
Improved
|
Kubota Y et al.[42] |
T2DM
|
40
|
FMD
|
Sitagliptin
|
None
|
12 w
|
Improved
|
Nystrom T et al.[43] |
T2DM
|
12
|
FMD
|
GLP-1
|
Saline
|
115 min
|
Improved
|
Koska J et al.[44] |
T2DM
|
28
|
PAT
|
Exendin-4
|
Saline
|
210 min
|
Improved
|
Noda Y et al.[45] |
Healty volunteer
|
10
|
FMD
|
Alogliptin
|
Placebo
|
1 w
|
Improved
|
van Poppel PC et al.[46] |
T2DM
|
16
|
Strain-gauged plethysmography
|
Vildagliptin
|
Acarbose
|
4 w
|
Improved
|
Ceriello A et al.[47] |
T2DM
|
28
|
FMD
|
GLP-1
|
Saline
|
2 h
|
Improved
|
Irace C et al.[48] |
T2DM
|
20
|
FMD
|
Exendin-4
|
Glimepiride
|
16w
|
Improved
|
Tesauro M et al.[37] |
Metabolic syndrome
|
10 (5/5)
|
Strain-gauged plethysmography
|
GLP-1
|
Saline
|
30 min
|
Improved (conditional)
|
Kelly AS et al.[38] |
IGT
|
50
|
PAT
|
Exendin-4
|
Metformin
|
6 m
|
No change
|
Hopkins ND, et al.[39] |
Obese T2DM
|
11
|
FMD
|
Exendin-4 (n = 9) Liragrutide (n = 2)
|
None
|
6 m
|
No change
|
Ayaori M et al.[40] |
T2DM
|
13 ~ 20,22
|
FMD
|
Sitagliptin/alogliptin
|
Voglibose
|
6 w
|
Worsened
|